Akero Therapeutics’ Product Efruxifermin Demonstrates Strong Positive Results in NASH Patients
July 1, 2020
0
Akero Therapeutics Efruxifermin Positive Results in NASH Akero Therapeutics (AKRO) results of a 16-week analysis of secondary and exploratory endpoints in Phase 2a BALANCED study of its product efruxifermin (EFX), formerly known as AKR-001, in patients with nonalcoholic steatohepatitis (NASH) are beating everybody’s expectations, including Akero Therapeutics. Of the 40 responders, the firm observed that 48% achieved at least a …
